| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Trauma, Hand and Reconstructive Surgery and Department of Nuclear Medicine, University of Ulm, Ulm
Department of Osteopathology, University of Hamburg, Hamburg, Germany
Correspondence: For correspondence or reprints contact: Michael Schulte, MD, Musculoskeletal Tumor Unit, Department of Trauma, Hand and Reconstructive Surgery, Steinhövelstr. 9, 89075 Ulm, Germany.
ABSTRACT
According to the current treatment protocol of the Cooperative Osteosarcoma Study (COSS), monitoring preoperative chemotherapy response and estimating grade of tumor regression in patients with osteosarcoma is mandatory before surgical removal of the tumor, particularly if a limb salvage procedure is intended. In addition, response to neoadjuvant chemotherapy is considered as an important prognostic indicator. The aim of this prospective study was to assess the usefulness of 2-(18F) fluoro-2-deoxy-D-glucose (FDG) PET in the noninvasive evaluation of neoadjuvant chemotherapy response in osteosarcoma. Methods: In 27 patients with osteosarcoma, we determined tumor-to-background ratios (TBRs) of FDG uptake with PET, before and after neoadjuvant chemotherapy according to COSS 86c or COSS 96 protocols, respectively. We compared changes in glucose metabolism of osteosarcomas with the histologic grade of regression in the resected specimen, according to Salzer-Kuntschik, discriminating responders (grades I–III; n = 17) and nonresponders (grades IV–VI; = 10). Results: The decrease of FDG uptake in osteosarcomas expressed as a ratio of posttherapeutic and pretherapeutic TBRs showed a close correlation to the amount of tumor necrosis induced by polychemotherapy (P < 0.001; Spearman). With a TBR ratio cutoff level of 0.6, all responders and 8 of 10 nonresponders could be identified by PET. In addition, lung metastases of osteosarcoma were detected with FDG PET in 4 patients. Conclusion: FDG PET provides a promising tool for noninvasive evaluation of neoadjuvant chemotherapy response in osteosarcoma. This could imply consequences for the choice of surgical strategy, because a limb salvage procedure cannot be recommended in patients nonresponsive to preoperative chemotherapy unless wide surgical margins can safely be achieved.
Key Words: osteosarcoma metabolism • osteosarcoma drug therapy • evaluation studies • osteosarcoma surgery • osteosarcoma radionuclide imaging
This article has been cited by other articles:
|
|
 |
|
  A. K. Buck, K. Herrmann, C. M. z. Buschenfelde, M. E. Juweid, M. Bischoff, G. Glatting, G. Weirich, P. Moller, H.-J. Wester, K. Scheidhauer, et al. Imaging Bone and Soft Tissue Tumors with the Proliferation Marker [18F]Fluorodeoxythymidine Clin. Cancer Res., May 15, 2008; 14(10): 2970 - 2977. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. C. Toner and R. J. Hicks PET for Sarcomas Other Than Gastrointestinal Stromal Tumors Oncologist, April 1, 2008; 13(suppl_2): 22 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Kim, S.-Y. Lee, W. H. Cho, W. S. Song, J.-S. Koh, J. A. Lee, J. Y. Yoo, and D.-G. Jeon Tumor Necrosis Rate Adjusted by Tumor Volume Change Is a Better Predictor of Survival of Localized Osteosarcoma Patients Ann. Surg. Oncol., March 1, 2008; 15(3): 906 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Biswal, D. L. Resnick, J. M. Hoffman, and S. S. Gambhir Molecular Imaging: Integration of Molecular Imaging into the Musculoskeletal Imaging Practice Radiology, September 1, 2007; 244(3): 651 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bernstein, H. Kovar, M. Paulussen, R. L. Randall, A. Schuck, L. A. Teot, and H. Juergensg Ewing's Sarcoma Family of Tumors: Current Management. Oncologist, May 1, 2006; 11(5): 503 - 519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W A Weber PET for response assessment in oncology: radiotherapy and chemotherapy Br. J. Radiol., November 1, 2005; Supplement_28(1): 42 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development Clin. Cancer Res., April 15, 2005; 11(8): 2785 - 2808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. C. Detterbeck, J. F. Vansteenkiste, D. E. Morris, C. A. Dooms, A. H. Khandani, and M. A. Socinski Seeking a Home for a PET, Part 3: Emerging Applications of Positron Emission Tomography Imaging in the Management of Patients With Lung Cancer Chest, November 1, 2004; 126(5): 1656 - 1666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Marina, M. Gebhardt, L. Teot, and R. Gorlick Biology and Therapeutic Advances for Pediatric Osteosarcoma Oncologist, July 1, 2004; 9(4): 422 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. Weber, V. Petersen, B. Schmidt, L. Tyndale-Hines, T. Link, C. Peschel, and M. Schwaiger Positron Emission Tomography in Non-Small-Cell Lung Cancer: Prediction of Response to Chemotherapy by Quantitative Assessment of Glucose Use J. Clin. Oncol., July 15, 2003; 21(14): 2651 - 2657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Brenner, K. H. Bohuslavizki, and J. F. Eary PET Imaging of Osteosarcoma J. Nucl. Med., June 1, 2003; 44(6): 930 - 942. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Franzius, S. Bielack, S. Flege, J. Sciuk, H. Jurgens, and O. Schober Prognostic Significance of 18F-FDG and 99mTc-Methylene Diphosphonate Uptake in Primary Osteosarcoma J. Nucl. Med., August 1, 2002; 43(8): 1012 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Franzius, H. E. Daldrup-Link, A. Wagner-Bohn, J. Sciuk, W. L. Heindel, H. Jurgens, and O. Schober FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging Ann. Onc., January 19, 2002; 13(1): 157 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. C. Eilber, G. Rosen, J. Eckardt, C. Forscher, S. D. Nelson, M. Selch, F. Dorey, and F. R. Eilber Treatment-Induced Pathologic Necrosis: A Predictor of Local Recurrence and Survival in Patients Receiving Neoadjuvant Therapy for High-Grade Extremity Soft Tissue Sarcomas J. Clin. Oncol., July 1, 2001; 19(13): 3203 - 3209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Schulte, D. Brecht-Krauss, B. Heymer, A. Guhlmann, E. Hartwig, M. R. Sarkar, C. G. Diederichs, A. V. Baer, J. Kotzerke, and S. N. Reske Grading of Tumors and Tumorlike Lesions of Bone: Evaluation by FDG PET J. Nucl. Med., October 1, 2000; 41(10): 1695 - 1701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Messa, C. Landoni, C. Pozzato, and F. Fazio Is There a Role for FDG PET in the Diagnosis of Musculoskeletal Neoplasms? J. Nucl. Med., October 1, 2000; 41(10): 1702 - 1702. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
